H-吴越投资2020-03-04 21:57
春节期间对血液灌流治疗进行初步研究,对采用全血灌流和血浆灌流的产品做了一些疏理,附以我个人的一些理解。相关公司列表如下:
表一、血浆吸附:
注:
(1)血浆吸附模式提前将血液中的血细胞分离出来,吸附效率更佳,还可以避免或减少血液相容性问题。血液相容性可能是因为离子树脂...查看全文
$Cytosorbents(CTSO)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-20-048793 Act: 34 Size: 721 KB 网页链接
$Cytosorbents(CTSO)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-20-048787 Act: 34 Size: 2 MB 网页链接
$Cytosorbents(CTSO)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001104659-20-048764 Act: 33 Size: 518 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001104659-20-048772 Act: 34 Size: 60 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-20-048762 Act: 34 Size: 64 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-20-047893 Act: 34 Size: 56 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, item 8.01 Accession Number: 0001104659-20-047709 Act: 34 Size: 33 KB 网页链接
$Cytosorbents(CTSO)$ 内部交易: 2020-03-10,COO,Capponi Vincent ,卖出,4677普通股, $6.00
$Cytosorbents(CTSO)$ 内部交易: 2020-03-10,COO,Capponi Vincent ,期权,11177普通股, $3.45
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-032715 Size: 14 KB 网页链接